US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

38.73

+0.23010.60%

Volume:839.12K

Turnover:32.45M

Market Cap:5.20B

PE:-11.12

High:40.07

Open:38.50

Low:38.10

Close:38.50

52wk High:49.70

52wk Low:8.70

Shares:134.37M

Float Shares:131.11M

Volume Ratio:0.51

T/O Rate:0.64%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.4823

EPS(LYR):-2.0600

ROE:-64.09%

ROA:-20.64%

PB:5.66

PE(LYR):-18.80

Loading ...

Overview Company News Filings

Definium Therapeutics DT120 data exceeds expectations, says Stifel

Definium Therapeutics Shares Jump on Strong Depression Drug Phase 3 Results

Definium Therapeutics Reports Positive Phase 3 DT120 Results

BUZZ-U.S. STOCKS ON THE MOVE- Visteon, Incyte, Apogee

BUZZ-Definium Therapeutics jumps as depression drug shows positive late-stage trial data

Definium's LSD-based depression pill delivers strong late-stage results, shares surge

Definium Therapeutics announces Emerge met primary endpoint

Definium Therapeutic Shares up 18.5% Premarket After Co's Lsd-Based Pill Reduces Depression Symptoms in Late-Stage Trial

THOMSON REUTERS

Definium Therapeutics - Phase 3 Emerge Study Meets Primary and All Key Secondary Efficacy Endpoints

THOMSON REUTERS

BRIEF-Definium Therapeutics Says Study Of DT120 ODT Met Primary All Key Secondary Efficacy Endpoints

Definium Therapeutics: Positive Topline Results From Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (Odt) in Major Depressive Disorder

THOMSON REUTERS

Definium Therapeutics: Study of DT120 Orally Disintegrating Tablet Met Primary & All Key Secondary Efficacy Endpoints

THOMSON REUTERS

Definium Therapeutics: DT120 Odt Was Generally Well Tolerated With No Serious Adverse Events or Suicidality Signal

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Definium Therapeutics to present Phase 3 Emerge topline data for DT120 ODT in major depressive disorder June 22

Definium Therapeutics to Discuss Topline Results From Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

THOMSON REUTERS

Definium Therapeutics Is Maintained at Buy by Canaccord Genuity

Definium Therapeutics issues inducement stock options for 155,480 shares to new hires

Definium Therapeutics Shareholders Approve All Annual Meeting Proposals

Definium Therapeutics shareholders approve 5 million-share increase to equity incentive plan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/DFTX/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DFTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":38.7301,"timestamp":1788377024781,"preClose":38.5,"halted":0,"volume":839120,"delay":0,"changeRate":0.005976623376623381,"floatShares":131114280,"shares":134366950,"eps":-3.482311,"marketStatus":"Trading","change":0.2301,"latestTime":"09-02 15:23:44 EDT","open":38.5,"high":40.065,"low":38.1,"amount":32446425.89872,"amplitude":0.051039,"askPrice":38.78,"askSize":13,"bidPrice":38.72,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-3.482311,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":38.5,"preHourTrading":{"tag":"盘前","latestPrice":38.3,"preClose":38.5,"latestTime":"09:27 EDT","volume":6540,"amount":246819.8616,"timestamp":1788355679328,"change":-0.2,"changeRate":-0.005195,"amplitude":0.037922},"postHourTrading":{"tag":"盘后","latestPrice":38.6,"preClose":38.5,"latestTime":"19:58 EDT","volume":24860,"amount":958344.1953,"timestamp":1788307117321,"change":0.1,"changeRate":0.002597,"amplitude":0.01974},"volumeRatio":0.508762,"impliedVol":1.0337,"impliedVolPercentile":0.6266},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","floatShares":131114280,"roa":"-20.64%","roe":"-64.09%","lyrEps":-2.059999,"volumeRatio":0.508762,"shares":134366950,"dividePrice":0,"high":40.065,"amplitude":0.051039,"preClose":38.5,"low":38.1,"week52Low":8.7,"pbRate":"5.66","week52High":49.7,"institutionHeld":0,"latestPrice":38.7301,"committee":0.877934,"eps":-3.482311,"divideRate":0,"volume":839120,"delay":0,"ttmEps":-3.482311,"open":38.5,"prevYearClose":13.39,"prevWeekClose":40.98,"prevMonthClose":39.72,"prevQuarterClose":47.04,"fiveDayClose":43.77,"twentyDayClose":44.39,"sixtyDayClose":23.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DFTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"DFTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.55,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-1.44},{"market":"US","date":"2026-05-07","symbol":"DFTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.47,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2026-02-26","symbol":"DFTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DFTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DFTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3889,"buy":0.6111,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6111,"analysts":18,"updateTime":1787025600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DFTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DFTX","date":"2026-09-01","current":-11.055876,"percent":0.307692,"low":-27.074722,"twenty":-17.384314,"median":-11.106728,"eighty":-9.894411,"high":-8.802064,"avg":-13.907193,"sd":5.5199,"marketCap":5337055254},"quantilePoints":[{"date":"2026-01-16","current":-9.013032,"twenty":-8.970838,"median":-8.907548,"eighty":-8.844258,"marketCap":1515072711},{"date":"2026-01-23","current":-9.944809,"twenty":-9.944809,"median":-9.423248,"eighty":-8.819645,"marketCap":1671702464},{"date":"2026-01-30","current":-10.103035,"twenty":-10.103035,"median":-9.868626,"eighty":-9.013032,"marketCap":1698299969},{"date":"2026-02-06","current":-9.522872,"twenty":-10.196799,"median":-9.918438,"eighty":-9.522872,"marketCap":1600775783},{"date":"2026-02-13","current":-9.511152,"twenty":-10.179218,"median":-9.944809,"eighty":-9.522872,"marketCap":1598805598},{"date":"2026-02-20","current":-10.120616,"twenty":-10.18039,"median":-9.944809,"eighty":-9.520528,"marketCap":1701255248},{"date":"2026-02-27","current":-9.267085,"twenty":-10.187422,"median":-9.96239,"eighty":-9.520528,"marketCap":1703225433},{"date":"2026-03-06","current":-9.519961,"twenty":-10.18039,"median":-9.903787,"eighty":-9.502065,"marketCap":1749702163},{"date":"2026-03-13","current":-9.753213,"twenty":-10.18039,"median":-9.918437,"eighty":-9.518199,"marketCap":1792572359},{"date":"2026-03-20","current":-10.122078,"twenty":-10.169841,"median":-9.903787,"eighty":-9.52229,"marketCap":1860367087},{"date":"2026-03-27","current":-10.273963,"twenty":-10.169841,"median":-9.918437,"eighty":-9.559599,"marketCap":1888282563},{"date":"2026-04-02","current":-11.174427,"twenty":-10.181562,"median":-9.918437,"eighty":-9.550417,"marketCap":2053781457},{"date":"2026-04-10","current":-11.619234,"twenty":-10.247114,"median":-9.944809,"eighty":-9.57529,"marketCap":2135533923},{"date":"2026-04-17","current":-12.18338,"twenty":-10.396104,"median":-9.980506,"eighty":-9.589394,"marketCap":2239219977},{"date":"2026-04-24","current":-12.617338,"twenty":-11.167918,"median":-10.038572,"eighty":-9.618687,"marketCap":2318978480},{"date":"2026-05-01","current":-11.86876,"twenty":-11.389236,"median":-10.10442,"eighty":-9.643639,"marketCap":2181395062},{"date":"2026-05-08","current":-13.767387,"twenty":-11.71579,"median":-10.122078,"eighty":-9.665202,"marketCap":2530349365},{"date":"2026-05-15","current":-9.802755,"twenty":-11.643102,"median":-10.113211,"eighty":-9.689477,"marketCap":2328575817},{"date":"2026-05-22","current":-10.399644,"twenty":-11.570414,"median":-10.105791,"eighty":-9.636028,"marketCap":2470362634},{"date":"2026-05-29","current":-10.780735,"twenty":-11.483622,"median":-10.120616,"eighty":-9.642537,"marketCap":2560888064},{"date":"2026-06-05","current":-11.290386,"twenty":-11.393576,"median":-10.145827,"eighty":-9.660184,"marketCap":2681952193},{"date":"2026-06-12","current":-11.069996,"twenty":-11.344489,"median":-10.179218,"eighty":-9.68473,"marketCap":2629600138},{"date":"2026-06-18","current":-11.216923,"twenty":-11.349156,"median":-10.196799,"eighty":-9.702279,"marketCap":2664501508},{"date":"2026-06-26","current":-20.565124,"twenty":-11.510745,"median":-10.247973,"eighty":-9.723056,"marketCap":4885101210},{"date":"2026-07-02","current":-24.252692,"twenty":-11.77112,"median":-10.299843,"eighty":-9.753213,"marketCap":5761057223},{"date":"2026-07-10","current":-27.074722,"twenty":-12.069466,"median":-10.333633,"eighty":-9.796609,"marketCap":6431410656},{"date":"2026-07-17","current":-24.643864,"twenty":-12.519698,"median":-10.492938,"eighty":-9.802755,"marketCap":5853977501},{"date":"2026-07-24","current":-23.990048,"twenty":-12.931958,"median":-10.537388,"eighty":-9.812883,"marketCap":5698667894},{"date":"2026-07-31","current":-24.861803,"twenty":-14.440728,"median":-10.67054,"eighty":-9.817222,"marketCap":5905747370},{"date":"2026-08-07","current":-17.312135,"twenty":-19.588062,"median":-10.789918,"eighty":-9.824231,"marketCap":6124773739},{"date":"2026-08-14","current":-16.673146,"twenty":-17.887875,"median":-10.831241,"eighty":-9.831914,"marketCap":5898709105},{"date":"2026-08-21","current":-17.242844,"twenty":-17.526933,"median":-11.058518,"eighty":-9.861594,"marketCap":6100259530},{"date":"2026-08-28","current":-16.642763,"twenty":-17.426666,"median":-11.092954,"eighty":-9.887379,"marketCap":5887959749},{"date":"2026-09-01","current":-15.085589,"twenty":-17.384314,"median":-11.106728,"eighty":-9.894411,"marketCap":5337055254}],"updateTime":1788341670804},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DFTX\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645078682","title":"Definium Therapeutics DT120 data exceeds expectations, says Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2645078682","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645078682?lang=en_us&edition=fundamental","pubTime":"2026-06-22 21:53","pubTimestamp":1782136387,"startTime":"0","endTime":"0","summary":"Stifel says “robust” major depressive disorder data reported by Definium Therapeutics (DFTX) for DT120 “exceeds expectations,” noting that the effe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-dt120-data-exceeds-expectations-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-dt120-data-exceeds-expectations-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4127","SF","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645217022","title":"Definium Therapeutics Shares Jump on Strong Depression Drug Phase 3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2645217022","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645217022?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:42","pubTimestamp":1782132120,"startTime":"0","endTime":"0","summary":"Definium Therapeutics shares surged in premarket trading Monday after the company reported strong phase 3 results for its experimental depression treatment.Shares traded 50% higher ahead of the morning bell at $36.74.The late-stage clinical biopharmaceutical company said patients receiving DT120, also known as lysergide, showed an improvement on a standard depression scale at week six, with effects emerging as early as the first week and lasting for up to 12 weeks.The Emerge study met its primary and all key secondary endpoints, including an eight-point placebo-adjusted reduction in symptoms by the sixth week.\"The Emerge topline results represent unprecedented and highly differentiated efficacy, demonstrating that a single dose of DT120 ODT can deliver rapid, robust, and durable relief in major depressive disorder,\" said Chief Executive Rob Barrow.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Definium Therapeutics Shares Jump on Strong Depression Drug Phase 3 Results","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022295","title":"Definium Therapeutics Reports Positive Phase 3 DT120 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022295","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645022295?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:38","pubTimestamp":1782131897,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Definium Therapeutics ( ($DFTX) ). On June 22, 2026, Definium Therapeutics reported positive topline results fr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-reports-positive-phase-3-dt120-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-reports-positive-phase-3-dt120-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645024876","title":"BUZZ-U.S. STOCKS ON THE MOVE- Visteon, Incyte, Apogee","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024876","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645024876?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:54","pubTimestamp":1782129252,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Visteon, Incyte, ApogeeWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL6N42U0MK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","LU1720051108.HKD","TSLW","LU2602419157.SGD","TSLG","BK4548","LU0198837287.USD","BK4516","LU0345769128.USD","LU2471134796.USD","LU2168564065.EUR","LU1551013425.SGD","CRSH","BK4563","HK0000914660.USD","LU0719512351.SGD","LU0820561909.HKD","LU0053671581.USD","LU0466842654.USD","BK4592","HOOG","LU1674673691.USD","TSLL","LU1852331112.SGD","LU0823414478.USD","TSLI","VC","BK4124","IE00BJLML261.HKD","BK4127","LU0133085943.USD","LU2471134523.USD","BK4585","LU0820562030.AUD","LU2087621335.USD","LU2750360997.AUD","LU0823411888.USD","LU2403377893.USD","LU1548497426.USD","ROBN","LU0345769631.USD","LU1366192091.USD","DFTX","LU2750360641.GBP","LU0053666078.USD","LU2168564495.EUR","SG9999015986.USD","HOOZ","IE00BK4W5L77.USD","LU0672654240.SGD","LU1861215975.USD","LU1861559042.SGD","TESL","LU1066051225.USD","LU1066051811.HKD","AVAL","BK4555","LU2896262040.SGD","IE00B1XK9C88.USD","LU2249611893.SGD","BK4099","INCY","LU0109391861.USD","LU2168564149.EUR","BK4574","IE00BWXC8680.SGD","LU2108987350.USD","GPRK","BK4588","LU0708995401.HKD","TSLA","TSLP","SG9999015945.SGD","SG9999015978.USD","IE00B19Z8W00.USD","LU0345770993.USD","HOOY","LU0234572021.USD","IE00B19Z8X17.USD","LU2326559502.SGD","LU2360107168.USD","SG9999015952.SGD","LU1267930730.SGD","HOOD","LU2756315318.SGD","LU0077335932.USD","TSL","IE00BK4W5M84.HKD","LU1815336091.USD","LU2023250330.USD","LU1839511570.USD","LU1066051498.USD","BK4533","LU0097036916.USD","TSLT","APGE","IE00B19Z9505.USD","IE00BSNM7G36.USD","TSYY","LU0345770308.USD","HK0000914686.HKD","BK4527","LU2756315664.SGD","TSLR","09366","LU1914381329.SGD","LU1720051017.SGD","BK4547","LU2168563687.JPY","LU2417539215.USD","LU1861558580.USD","BK4505","TSLY","LU1066053197.SGD","BK4543","LU1629891620.HKD","LU2063271972.USD","LU0320765059.SGD","IE0034235303.USD","LU0943347566.SGD","LU2290526834.HKD","LU1861220033.SGD","BK4007","LU1674673428.USD","LU0210536198.USD","BK4581","BK4604","HOII","RGNX","07766","BK4511","HODU","LU0082616367.USD","LU2357305700.SGD","LU2462157665.USD","LU2456880835.USD","LU1435385759.SGD","LU2168564222.USD","LU2471134879.HKD","LU0964807845.USD","BK4207","LU1429558221.USD","TSLO","TEST","TLA","LU1232071149.USD","BK4551","LU0820561818.USD","07366","BK4550","LU2250418816.HKD","LU2236285917.USD","LU2360106780.USD","TSLQ","BK4139","HOYY","TSDD","LU0316494557.USD","IE00B1BXHZ80.USD","LU0056508442.USD","BK4612","BK4539","BK4532","LU0757428866.USD","LU0348723411.USD","TSLZ","HOOI","LU0689472784.USD","TSLS","LU0234570918.USD","LU2213496289.HKD","BK4598","HOOX","LU1145028129.USD","IE00BZ199S13.USD","LU0323591593.USD","BK4534","HOOW","LU1778281490.HKD","TSII","09766","LU2471134952.CNY","LU2420271590.USD","LU1551013342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029056","title":"BUZZ-Definium Therapeutics jumps as depression drug shows positive late-stage trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029056","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029056?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:13","pubTimestamp":1782126785,"startTime":"0","endTime":"0","summary":"BUZZ-Definium Therapeutics jumps as depression drug shows positive late-stage trial data** Shares of biotech firm Definium Therapeutics DFTX.O rise 19% to $25.02 premarket** Co says DT120, an experimental oral drug for major depressive disorder, a common mental health condition causing persistent low mood, met main goal in late-stage study** Says patients showed 8.1-point greater improvement in depression scores vs placebo after six weeks** DFTX says benefit seen within one week and remained significant at 12 weeks** Says DT120, based on lysergide , was generally well tolerated with no serious safety concerns** Co plans to advance DT120 toward regulatory review; also testing in anxiety and PTSD** As of last close, stock up ~83% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U0RW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029776","title":"Definium's LSD-based depression pill delivers strong late-stage results, shares surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029776","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029776?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:11","pubTimestamp":1782126682,"startTime":"0","endTime":"0","summary":"UPDATE 2-Definium's LSD-based depression pill delivers strong late-stage results, shares surgeUpdates share movement, adds analyst comment 6 and 7, background throughoutBy Kamal Choudhury","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U0S5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1121112475.USD","LU1057294990.SGD","LU0689626769.HKD","LU1496350502.SGD","LU2236285917.USD","LU2471134952.CNY","LU2756315664.SGD","AXSM","BK4550","JNJ","LU1162221912.USD","LU0683600562.USD","IE0002270589.USD","LU0432979614.USD","LU1778281490.HKD","LU0210528500.USD","LU1043141123.HKD","LU2456880835.USD","BK4504","LU1244550577.SGD","SGXZ57979304.SGD","LU1074936037.SGD","LU1196500208.SGD","LU0122379950.USD","LU0070217475.USD","CMPS","SG9999001176.SGD","DFTX","LU1894683264.USD","LU1551013342.USD","LU2896262040.SGD","IE00BKVL7J92.USD","LU0466842654.USD","IE00BN8TJ469.HKD","IE0001KFT4U8.USD","SUPN","LU0345769631.USD","IE00B4R5TH58.HKD","SG9999013999.USD","LU2417539215.USD","LU0053666078.USD","LU1244550221.USD","LU0943347566.SGD","LU1244550494.USD","LU1914381329.SGD","LU0124676726.USD","LU1929549753.HKD","LU2430703251.USD","LU1551013425.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645702153","title":"Definium Therapeutics announces Emerge met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2645702153","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645702153?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:08","pubTimestamp":1782126483,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (DFTX) announced positive topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase 3 study e...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-announces-emerge-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-announces-emerge-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029259","title":"Definium Therapeutic Shares up 18.5% Premarket After Co's Lsd-Based Pill Reduces Depression Symptoms in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029259?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:07","pubTimestamp":1782126456,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U0S3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645296790","title":"Definium Therapeutics - Phase 3 Emerge Study Meets Primary and All Key Secondary Efficacy Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2645296790","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645296790?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUABJ07L5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645024357","title":"BRIEF-Definium Therapeutics Says Study Of DT120 ODT Met Primary All Key Secondary Efficacy Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024357","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645024357?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126001,"startTime":"0","endTime":"0","summary":"BRIEF-Definium Therapeutics Says Study Of DT120 ODT Met Primary All Key Secondary Efficacy EndpointsJune 22  - Definium Therapeutics Inc DFTX.O:DEFINIUM THERAPEUTICS: POSITIVE TOPLINE RESULTS FROM PHASE 3 EMERGE STUDY OF DT120 ORALLY DISINTEGRATING TABLET  IN MAJOR DEPRESSIVE DISORDERDEFINIUM THERAPEUTICS: STUDY OF DT120 ORALLY DISINTEGRATING TABLET MET PRIMARY  ALL KEY SECONDARY EFFICACY ENDPOINTSDEFINIUM THERAPEUTICS: DT120 ODT WAS GENERALLY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS OR SUICIDALITY SIGNAL ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nP8N42502Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645293100","title":"Definium Therapeutics: Positive Topline Results From Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (Odt) in Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2645293100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645293100?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nP8N42502Y:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029348","title":"Definium Therapeutics: Study of DT120 Orally Disintegrating Tablet Met Primary & All Key Secondary Efficacy Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029348","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029348?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nP8N42502Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029317","title":"Definium Therapeutics: DT120 Odt Was Generally Well Tolerated With No Serious Adverse Events or Suicidality Signal","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029317?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nP8N42502Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645042865","title":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon","url":"https://stock-news.laohu8.com/highlight/detail?id=2645042865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645042865?lang=en_us&edition=fundamental","pubTime":"2026-06-22 15:47","pubTimestamp":1782114448,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, VisteonJune 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U0H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AALG","CNXU","ABVX","INTC","LQDA","MTDR","MRNX","BILL","BWXT","ALT","KR","FMC","DCH","KLAC","KLAG","HCA","INTW","FTH","DFTX","AMAT","BWIN","MRK","MULL","FPS","AMRZ","DAR","GLW","LRCU","ENPH","FANG","LRCX","LINT","VC","KMX","MUU","CHRD","NBIX","DAL","MRNY","BYD","LGN","ALGM","APGE","ARMK","MU","MRNA","AGMB","INCY","AAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645164840","title":"Definium Therapeutics to present Phase 3 Emerge topline data for DT120 ODT in major depressive disorder June 22","url":"https://stock-news.laohu8.com/highlight/detail?id=2645164840","media":"Reuters","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645164840?lang=en_us&edition=fundamental","pubTime":"2026-06-22 05:00","pubTimestamp":1782075628,"startTime":"0","endTime":"0","summary":"Definium Therapeutics scheduled a June 22, 2026 webcast to present topline Phase 3 Emerge results for DT120 ODT in major depressive disorder.The trial tested a single-dose treatment against placebo, with efficacy assessed over several weeks.Management plans to discuss whether DT120 produced meaningful symptom improvement versus placebo, alongside the overall safety profile, without releasing detailed metrics in advance.Emerge is the first of two pivotal Phase 3 studies; a second trial, Ascend, is running with an additional lower-dose arm to support the program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on June 21, 2026, an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260621:nNDL6nkKwk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645016483","title":"Definium Therapeutics to Discuss Topline Results From Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645016483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645016483?lang=en_us&edition=fundamental","pubTime":"2026-06-22 05:00","pubTimestamp":1782075601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260621:nTUA1K8DQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644766231","title":"Definium Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2644766231","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644766231?lang=en_us&edition=fundamental","pubTime":"2026-06-16 23:59","pubTimestamp":1781625540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DFTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2026 11:59 ET (15:59 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643785383","title":"Definium Therapeutics issues inducement stock options for 155,480 shares to new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2643785383","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643785383?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:01","pubTimestamp":1781553672,"startTime":"0","endTime":"0","summary":"Definium Therapeutics issued inducement stock options covering 155,480 common shares to six newly hired non-executive employees.Options carry an exercise price set at the closing share price on June 15, 2026.Vesting spans four years: 25% after one year, remaining 75% in substantially equal monthly installments over the next three years.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL9m0ZGF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643740215","title":"Definium Therapeutics Shareholders Approve All Annual Meeting Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2643740215","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643740215?lang=en_us&edition=fundamental","pubTime":"2026-06-13 07:05","pubTimestamp":1781305522,"startTime":"0","endTime":"0","summary":"Definium Therapeutics ( ($DFTX) ) has issued an announcement. On June 11, 2026, Definium Therapeutics, Inc. held its Annual Meeting, where a quorum...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-shareholders-approve-all-annual-meeting-proposals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-shareholders-approve-all-annual-meeting-proposals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643940218","title":"Definium Therapeutics shareholders approve 5 million-share increase to equity incentive plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2643940218","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643940218?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:31","pubTimestamp":1781296272,"startTime":"0","endTime":"0","summary":"Definium Therapeutics held its annual general and special meeting of shareholders on June 11, 2026.Shareholders passed an amendment to the 2025 Equity Incentive Plan, lifting the share reserve by 5 million common shares; the amendment took effect on approval.KPMG LLP was reappointed as independent registered public accounting firm through the 2027 annual meeting.Shareholders also voted in favor of the company’s slate of seven board nominees to serve until the 2027 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Comm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL7ZF4y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}